Bulent Degertekin, MD; Anna S.F. Lok, MD
Grant Support: By Ufuk University Faculty of Medicine, Ankara, Turkey (Dr. Degertekin), and the Tuktawa Fund for Liver Research and Education at the University of Michigan (Dr. Lok). Dr. Lok is supported in part by National Institutes of Health contract N01 DK-9-2323 and grants U01 DK57577 and U01 DK62498.
Potential Financial Conflicts of Interest: Consultancies: A.S.F. Lok (Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Idenix, Innogenetics, Pharmasset, Roche, Schering-Plough); Grants received: A.S.F. Lok (Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Idenix, Innogenetics, Roche, Schering-Plough).
Requests for Single Reprints: Anna S.F. Lok, MD, Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, Ann Arbor, MI 48109-0362; e-mail, email@example.com.
Current Author Addresses: Drs. Degertekin and Lok: Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, Ann Arbor, MI 48109-0362.
Learn more about subscription options.
Register Now for a free account.
Degertekin B, Lok AS. When to Start and Stop Hepatitis B Treatment: Can One Set of Criteria Apply to All Patients Regardless of Age at Infection?. Ann Intern Med. 2007;147:62–64. doi: 10.7326/0003-4819-147-1-200707030-00011
Download citation file:
Published: Ann Intern Med. 2007;147(1):62-64.
Gastroenterology/Hepatology, Infectious Disease, Liver Disease, Viral Hepatitis.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only